Internal Medicine, Endocrinology, Diabetes, & Metabolism · Miami, FL
NPI
1568411262
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
2828 Coral Way Ste 309
Miami, FL, 33145
Phone (305) 273-1919
Medicare paid, 2024
$74K
736 services
Medicare patients, 2024
327
Average age 73
Drug cost, 2024
$5.0M
10,651 prescriptions
Company payments, 2025
$112
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth B Shephard was code 99214 (office e&m - established), 465 times for 252 patients. In total Kenneth B Shephard billed 736 services in 10 codes, and Medicare paid $74K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-08-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 465 | 252 | $102.46 | $48K |
| 99204 Office E&M - New | Office | 84 | 84 | $139.86 | $12K |
| 99213 Office E&M - Established | Office | 83 | 68 | $70.39 | $5,842 |
| 76536 Ultrasound - Nonspecific | Office | 73 | 70 | $85.42 | $6,236 |
| 10005 Other Organ Systems | Office | 18 | 16 | $112.52 | $2,025 |
By year: 2022 $92K for 887 services; 2023 $74K for 755 services; 2024 $74K for 736 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth B Shephard prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,162 prescriptions and refills. In total Kenneth B Shephard wrote 10,651 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,162 | 2,757 | 368 | $11K |
| Mounjaro Tirzepatide | 939 | 982 | 183 | $1.0M |
| Ozempic Semaglutide | 851 | 985 | 186 | $864K |
| Jardiance Empagliflozin | 590 | 801 | 160 | $478K |
| Synjardy Empagliflozin/Metformin Hcl | 403 | 500 | 102 | $244K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 399 | 799 | 145 | $37K |
| Pioglitazone Hcl Generic | 381 | 658 | 113 | $2,556 |
| Tresiba Flextouch U-100 Insulin Degludec | 302 | 490 | 80 | $155K |
| Synthroid Levothyroxine Sodium | 300 | 663 | 81 | $28K |
| Glimepiride Generic | 261 | 621 | 103 | $2,821 |
| Humalog Kwikpen U-100 Insulin Lispro | 253 | 394 | 87 | $68K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 227 | 407 | 69 | $31K |
| Rybelsus Semaglutide | 222 | 257 | 66 | $244K |
| Methimazole Generic | 210 | 384 | 67 | $2,029 |
| Metformin Hcl Generic | 204 | 560 | 86 | $1,146 |
Brand drugs: 7,207 claims; generic drugs: 2,583 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth B Shephard $112 ($112 in general payments such as food, travel and fees) from 3 companies. The largest payer was Insulet Corporation with $55.75.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.